2917-LB: Prescribing Practices and Clinical Support for GLP-1 Receptor Agonists in Youth-Onset Type 2 Diabetes: Data from the T1DX QI Collaborative

Le résumé fourni par la source

Introduction and Objective: The ADA recommends GLP-1 RAs in youth onset type 2 diabetes (YO-T2D) when glycemic targets are not met with metformin. We aimed to assess access to and usage of GLP-1 RAs in YO-T2D across pediatric diabetes centers within the T1D Exchange QI Collaborative (T1DX-QI). Methods: The 2025 T1DX-QI annual survey was administered to all member centers. Responses were collected from representatives at each center. Descriptive analyses summarized GLP-1 RA use, insurance coverage, access, and monitoring. Results: Among 42 responding pediatric centers 88% reported GLP-1 RA coverage for YO-T2D for privately insured and 81% for publicly insured patients. Estimated GLP-1 RA use varied widely with 25 centers reporting that ≤50% of patients with YO-T2D were prescribed GLP-1 RAs. Only 31% of centers reported having structured follow-up protocols with most centers relying on patients to schedule clinic visits instead of proactive outreach between appointments. Conclusion: Reports of insurance coverage for GLP-1 RAs in YO-T2D were variable based on insurance type and prescribing rates were low for several centers, suggesting opportunities to support prescribers and patients in accessing GLP-1 RAs. Disclosure Y. Naik: None. D. Vora: None. M. Bianco: None. T.S. Hannon: None. C. Schweisberger: None. S. Accacha: None. M.V. Vakharia: Consultant; Current; Dexcom, Inc. O. Odugbesan: None. Funding Leona M. and Harry B. Helmsley Charitable Trust

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.